Pharmaceutical policy in China
Pharmaceutical policy in China
复制标题
DOI：
10.1377/hlthaff.27.4.1042
复制
发表时间：
2008-07-01
期刊：
影响因子：
9.7
通讯作者：
Eggleston, Karen
中科院分区：
文献类型：
--
作者：
Sun, Qiang;Santoro, Michael A.;Eggleston, Karen
矛盾的目标困扰着中国的医药政策。政府希望发展国内制药行业，并利用药品定价交叉补贴公立医院。然而，政府还旨在通过价格上限和利润率监管来控制药品支出，以确保即使是贫困患者也能获得药品。由此产生的制度扭曲了市场激励，增加了消费者的成本，并在经济上奖励了不适当的处方，从而损害了公众健康。在中国，药品约占总医疗费用的一半，占每次住院费用的43%，占每次门诊费用的51%。然而，一些基本药物是无法获得的，或者质量有问题。
Contradictory goals plague China's pharmaceutical policy. The government wants to develop the domestic pharmaceutical industry and has used drug pricing to cross subsidize public hospitals. Yet the government also aims to control drug spending through price caps and profit-margin regulations to guarantee access even for poor patients. The resulting system has distorted market incentives, increased consumers' costs, and financially rewarded inappropriate prescribing, thus undermining public health. Pharmaceuticals account for about half of total health spending in China, representing 43 percent of spending per inpatient episode and 51 percent of spending per outpatient visit. Yet some essential medicines are unavailable or of questionable quality.